Overview

A Bioequivalence (BE) Study in Healthy Subjects

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

To demonstrate the bioequivalence of 12.5 milliliters (mL) of atomoxetine oral solution (4 milligrams per milliliter [mg/mL]) compared with 2 capsules of atomoxetine (25 mg per capsule) in healthy adult male Japanese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atomoxetine Hydrochloride